Chinese biopharmaceutical firm RemeGen announced on Tuesday the completion of over $100 million in a new funding round jointly led China-based biomedical venture capital firm Lilly Asia Ventures, and Hong Kong’s healthcare investment fund Lake Bleu Capital.
Global healthcare investment firm Vivo Capital, Janchor Partners, a long-term industrialist investor led by John Ho in Hong Kong, New York-based investment manager Hudson Bay Capital, and OrbiMed, which manages $14 billion for healthcare investment, and existing investors participated in the new round.
